File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Wait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts

TitleWait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts
Authors
KeywordsHepatocellular carcinoma
Liver transplantation
Grafts
Issue Date2013
Citation
Transplantation, 2013, v. 96, n. 11, p. 995-999 How to Cite?
AbstractBACKGROUND: As a new scheme at our center, a Model for End-stage Liver Disease score of 18 points is assigned to candidates of deceased-donor liver transplantation (DDLT) who have hepatocellular carcinoma (HCC) remaining at stage 2 six months after their disease has been confirmed stage 2 HCC. Two points are added every 3 months if their disease remains at stage 2 or below. This study evaluated patient and tumor characteristics as well as surgical and short-term outcomes of DDLT in these patients. METHODS: Comparison of survival was made among three groups of patients who underwent liver transplantation (LT) in the same period. Group 1 consisted of 22 HCC patients who received DDLT under the new scheme. Group 2 consisted of 18 HCC patients who underwent living-donor LT. Group 3 consisted of 52 patients who underwent DDLT because of liver failure, among whom 6 had HCC but were not included in the new scheme. RESULTS: Group 1 had a median follow-up period of 17.9 months, and the 1-, 3-, and 5-year overall survival rates were 100%, 100%, and 80%, respectively. Group 2 had the corresponding rates at 100%, 100%, and 100% with a median follow-up of 19.6 months. Group 3 had the corresponding rates at 96.1%, 96.1%, and 96.1% with a median follow-up of 19.4 months. CONCLUSIONS: The policy of a 6-month wait has benefited the HCC patients who practically had no chance of undergoing living-donor LT. Their survival outcomes will be excellent as long as they can stand the test of time. © 2013 by Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/221353
ISSN
2015 Impact Factor: 3.69
2015 SCImago Journal Rankings: 1.699
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, SC-
dc.contributor.authorSharr, WW-
dc.contributor.authorChok, KSH-
dc.contributor.authorChan, ACY-
dc.contributor.authorLo, CM-
dc.date.accessioned2015-11-18T06:09:05Z-
dc.date.available2015-11-18T06:09:05Z-
dc.date.issued2013-
dc.identifier.citationTransplantation, 2013, v. 96, n. 11, p. 995-999-
dc.identifier.issn0041-1337-
dc.identifier.urihttp://hdl.handle.net/10722/221353-
dc.description.abstractBACKGROUND: As a new scheme at our center, a Model for End-stage Liver Disease score of 18 points is assigned to candidates of deceased-donor liver transplantation (DDLT) who have hepatocellular carcinoma (HCC) remaining at stage 2 six months after their disease has been confirmed stage 2 HCC. Two points are added every 3 months if their disease remains at stage 2 or below. This study evaluated patient and tumor characteristics as well as surgical and short-term outcomes of DDLT in these patients. METHODS: Comparison of survival was made among three groups of patients who underwent liver transplantation (LT) in the same period. Group 1 consisted of 22 HCC patients who received DDLT under the new scheme. Group 2 consisted of 18 HCC patients who underwent living-donor LT. Group 3 consisted of 52 patients who underwent DDLT because of liver failure, among whom 6 had HCC but were not included in the new scheme. RESULTS: Group 1 had a median follow-up period of 17.9 months, and the 1-, 3-, and 5-year overall survival rates were 100%, 100%, and 80%, respectively. Group 2 had the corresponding rates at 100%, 100%, and 100% with a median follow-up of 19.6 months. Group 3 had the corresponding rates at 96.1%, 96.1%, and 96.1% with a median follow-up of 19.4 months. CONCLUSIONS: The policy of a 6-month wait has benefited the HCC patients who practically had no chance of undergoing living-donor LT. Their survival outcomes will be excellent as long as they can stand the test of time. © 2013 by Lippincott Williams & Wilkins.-
dc.languageeng-
dc.relation.ispartofTransplantation-
dc.subjectHepatocellular carcinoma-
dc.subjectLiver transplantation-
dc.subjectGrafts-
dc.titleWait and transplant for stage 2 hepatocellular carcinoma with deceased-donor liver grafts-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1097/TP.0b013e3182a339a7-
dc.identifier.pmid23924774-
dc.identifier.scopuseid_2-s2.0-84889878587-
dc.identifier.hkuros220305-
dc.identifier.volume96-
dc.identifier.issue11-
dc.identifier.spage995-
dc.identifier.epage999-
dc.identifier.isiWOS:000330435400015-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats